Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Histopathologic and Physiologic Profile in Esophageal Motility Disorders
NCT04641702Phase 4Recruiting
- Sponsor
- Emory University
- Start
- Mar 2021
- Primary completion
- Dec 2028
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atropine in achalasia and esophageal motility disorder (EMD) (3 arms), sponsored by Emory University. Primary endpoints: Degree of lower esophageal sphincter contraction and relaxation at 2 minutes and Collagen content in muscle biopsy specimens at 2 minutes. Started Mar 2021; status: recruiting.
02
Drugs
atropine
03
Conditions
achalasiaesophageal motility disorder (EMD)
Beyond the preview
Go deeper on NCT04641702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641702.